Apr 01, 2026 (PRISM News via COMTEX) --
Cyclerion Therapeutics (NASDAQ: CYCN) surged more than 300% following the announcement of a definitive all-stock merger with private biotech Korsana Biosciences.
The combined company will operate as Korsana Biosciences and trade under the ticker KRSA, with closing expected in Q3 2026. Existing CYCN shareholders are expected to own approximately 1.5% of the combined entity.
Korsana is advancing therapies for neurodegenerative diseases, including a lead Alzheimer's program targeting amyloid beta. In connection with the transaction, the company secured $380 million in oversubscribed financing from leading healthcare investors, providing runway into 2029.
The deal reflects a familiar biotech reset structure, pairing a public listing with a newly funded pipeline and significant capital backing.
The post CYCN Surges on Korsana Merger and $380M Financing appeared first on PRISM MarketView.
COMTEX_476369699/2927/2026-04-01T11:01:26
